Clinical Trials List
Protocol NumberMK-2400-01A
Active
2025-04-15 - 2032-12-31
Phase I/II
Recruiting2
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 張瓈文 Division of Urology
- 楊哲瑞 Division of Urology
- 蔡世傳 Division of Nuclear Medicine
- 林雁婷 Division of Radiology
- 梅承恩 Division of Urology
- Cheng-Kuang Yang Division of Urology
- 賴谷順 Division of Urology
- Shian-Shiang Wang Division of Urology
- 洪晟鈞 Division of Urology
- Cheng-Che Chen Division of Urology
- 楊涵中 Division of Urology
- Chia-Yen Lin Division of Urology
- 王樹吉 Division of Urology
- 張家程 Division of Urology
- Chuan-Shu Chen Division of Urology
- 裘坤元 Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 沈書慧 Division of Radiology
- Tzu-Hsiang Hsu Division of Urology
- 蔡承翰 Division of Urology
- Chih-Chieh Lin Division of Urology
- Tzu-Hao Huang Division of Urology
- Hsiao-Jen Chung Division of Urology
- 柯玉潔 Division of Ophthalmology
- William Huang Division of Urology
- Tzu-chun Wei Division of Urology
- Chien-Hsin Ting Division of Nuclear Medicine
- Yen-Hwa Chang Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
8 participants
-
Global
360 participants
